Evidence map›Paper›PMID 40395199›Full record

ArticleAsia-Pacific journal of clinical oncology2026

Post-Therapeutic Dosimetry of Metastatic Castration-Resistant Prostate Cancer With

Onnicha Pattanawong, Putthiporn Charoenphun, Wichana Chamroonrat, Thonnapong Thongpraparn, Nucharee Poon-Iad, Benjapa Khiewvan, Krisanat Chuamsaamarkkee

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Asia-Pacific journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Onnicha PattanawongMaster of Science Program in Medical Physics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Putthiporn CharoenphunMaster of Science Program in Medical Physics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Wichana ChamroonratDivision of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Thonnapong ThongpraparnDivision of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Nucharee Poon-IadDivision of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Benjapa KhiewvanDivision of Nuclear Medicine, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Krisanat ChuamsaamarkkeeMaster of Science Program in Medical Physics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.ORCID https://orcid.org/0000-0002-0362-9125

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objective

methodsWe retrospectively analyzed 61 treatment cycles in 36 patients who underwent posttreatment whole-body planar imaging at three time points (1, 24, and 168 h postadministration). Absorbed doses were computed using organ based MIRD (Medical Internal Radiation Dosimetry) method with OLINDA/EXM v.2.2 in Hermes dosimetry software.

resultsThe median treated activity was 5.79 GBq (range 5.00-7.29 GBq). Normal organ absorbed doses, from lowest to highest, were red marrow (0.03 ± 0.03 Gy/GBq), total body (0.04 ± 0.03 Gy/GBq), liver (0.13 ± 0.33 Gy/GBq), salivary glands (0.65 ± 0.42 Gy/GBq), and kidneys (0.72 ± 0.36 Gy/GBq).

conclusionAbsorbed doses to normal organs remained within an acceptable range and not exceed the tolerance limits.

Indexed as

LutetiumProstatic Neoplasms, Castration-ResistantRadioisotopesRadiopharmaceuticalsAgedAged, 80 and overHospitals, UniversityHumansMaleMiddle AgedProstate-Specific AntigenRadiometryRetrospective StudiesThailandLutetiumLutetium-177PluvictoProstate-Specific AntigenRadioisotopesRadiopharmaceuticals177Lu‐PSMAdosimetryprostate cancerradioligand therapy

Identifiers

PMID40395199
PMCPMC13007747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.